Blockchain Registration Transaction Record

Regentis Advances GelrinC® for Knee Cartilage Repair, Targeting $3B Market

Regentis Biomaterials advances GelrinC®, a cell-free hydrogel implant for knee cartilage repair, targeting a $3B U.S. market with Phase III trial progress and CE Mark approval.

This news matters because knee cartilage damage affects millions, often leading to pain and reduced mobility. Current treatments like microfracture have limited efficacy, while cell-based therapies are complex and costly. GelrinC® offers a potential off-the-shelf, minimally invasive solution that could significantly improve patient outcomes, reduce recovery times, and lower healthcare costs. For investors, Regentis is approaching key regulatory milestones that could drive substantial value.